INTERVIEW: Albireo’s CEO Ron Cooper Talks Patient-Centricity, PFIC, and Study Updates

Each week, in an email to his team, Albireo Pharma CEO Ron Cooper sends out the story of a child or family affected by conditions such as PFIC or Alagille…

Continue Reading INTERVIEW: Albireo’s CEO Ron Cooper Talks Patient-Centricity, PFIC, and Study Updates
INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 2)
Photo courtesy of Mirum

INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 2)

Before you read on, make sure to check out Part 1 of our interview. In Part 1, Chris Peetz discusses his background, why he joined Mirum, and the process of evaluating LIVMARLI…

Continue Reading INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 2)
INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 1)
Photo courtesy of Mirum

INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 1)

The American Association for the Study of Liver Disease (AASLD) held its annual Liver Meeting from November 4-7, 2022 in Washington, D.C. During the meeting, Mirum Pharmaceuticals shared two late-breaker…

Continue Reading INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 1)

FDA Approves Bylvay for Treatment of Progressive Familial Intrahepatic Cholestasis

  According to a recent press release from Globe Newswire, Albireo Pharma announced that Lancet Gastroenterology published results of the PEDFIC 1 trial evaluating Bylvay® in the treatment of progressive…

Continue Reading FDA Approves Bylvay for Treatment of Progressive Familial Intrahepatic Cholestasis
Trial Data Shows Benefit of Bylvay Dose Escalation in Progressive Familial Intrahepatic Cholestasis
source: pixabay.com

Trial Data Shows Benefit of Bylvay Dose Escalation in Progressive Familial Intrahepatic Cholestasis

According to a story from Globe Newswire, the rare disease company Albireo Pharma, Inc. has recently announced the release of new data from its phase 3 trials. These trials were…

Continue Reading Trial Data Shows Benefit of Bylvay Dose Escalation in Progressive Familial Intrahepatic Cholestasis
One Family’s Story on Being Diagnosed with Progressive Familial Intrahepatic Cholangitis
Source: Pixabay.com

One Family’s Story on Being Diagnosed with Progressive Familial Intrahepatic Cholangitis

A recent article shared the story of one family’s journey with multiple family members being diagnosed with progressive familial intrahepatic cholangitis (PFIC) after years of medical issues. Progressive Familial Intrahepatic…

Continue Reading One Family’s Story on Being Diagnosed with Progressive Familial Intrahepatic Cholangitis
Bylvay Recommended for Progressive Familial Intrahepatic Cholestasis in Europe
source: pixabay.com

Bylvay Recommended for Progressive Familial Intrahepatic Cholestasis in Europe

In the past, treatment for progressive familial intrahepatic cholestasis (PFIC) was symptomatic or surgical, meaning that there weren't too many treatment options for this patient population. This all changed with…

Continue Reading Bylvay Recommended for Progressive Familial Intrahepatic Cholestasis in Europe
NDA for Potential Progressive Familial Intrahepatic Cholestasis Treatment Cleared by FDA
source: pixabay.com

NDA for Potential Progressive Familial Intrahepatic Cholestasis Treatment Cleared by FDA

According to a press release from the rare liver disease company Albireo Pharma, Inc., the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for odevixibat.…

Continue Reading NDA for Potential Progressive Familial Intrahepatic Cholestasis Treatment Cleared by FDA
Odevixibat Shows Promise in Progressive Familial Intrahepatic Cholestasis
source: pixabay.com

Odevixibat Shows Promise in Progressive Familial Intrahepatic Cholestasis

According to a story from GlobeNewswire, the rare disease liver company Albireo Pharma, Inc., recently announced positive results from a phase 3 study testing the company's experimental drug odevixibat as…

Continue Reading Odevixibat Shows Promise in Progressive Familial Intrahepatic Cholestasis

New 5-Year Survival Data Available on Maralixibat for PFIC2

This year, the Digital International Liver Congress took place online from August 27-29, thanks to COVID-19. During the conference, biopharmaceutical company Mirum Pharmaceuticals announced data from its Phase 2 INDIGO…

Continue Reading New 5-Year Survival Data Available on Maralixibat for PFIC2

Progressive Familial Intrahepatic Cholestasis Online Support Groups Provide Comfort During COVID-19

Claire Brinkley Claire Brinkley's daughter Eleanor is diagnosed with progressive familial intrahepatic cholestasis (PFIC) which is a rare disease affecting the liver. As a newborn, she appeared perfectly normal. But at…

Continue Reading Progressive Familial Intrahepatic Cholestasis Online Support Groups Provide Comfort During COVID-19

“The Way That Everyone is Acting Now? Unfortunately, Thats Sort of How We Normally Run Our Lives.” A Immunosuppressed Patient And COVID-19.

Brooke Ramirez's pregnancy with her first daughter went as planned, and her new baby Trinity passed her developmental milestones. It wasn't until she was five months old that they noticed…

Continue Reading “The Way That Everyone is Acting Now? Unfortunately, Thats Sort of How We Normally Run Our Lives.” A Immunosuppressed Patient And COVID-19.